Furthermore, administration of the TGR5 agonist inhibited portal hypertension in mice treated for 9 weeks with CCl4, while it did not affect fibrosis development [53], suggesting an effect on the hepatic microvasculature independent of extracellular matrix deposition. The gene discussed is GPBAR1; the disease is liver disorder.